Alitretinoin Details - The People's Medicine Community

Alitretinoin

Home

Alitretinoin

Drug Details

Clinical uses

Kaposis sarcoma

In the United States, topical alitretinoin (trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma. Alitretinoin is not indicated when systemic therapy against Kaposi's sarcoma is required.^[2]

Chronic hand eczema

Under the trade name Toctino (marketed by Basilea, Switzerland) it has been granted prescription rights in the UK (08/09/2008) for oral use in chronic hand eczema.^[3] In May 2009 the National Institute for Health and Clinical Excellence (NICE) issued preliminary guidance^[4] on the use of Alitretinoin for the treatment of severe chronic hand eczema in adults. The recommendation stated that only patients with severe chronic hand eczema who are unresponsive to potent topical corticosteroids, oral immunosuppressants or phototherapy should receive the drug. Final NICE guidance is expected in August 2009.

References

^ WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcddd/new_atc_ddd.html#ATCDDD_FINAL. Retrieved 2008-09-05.
^ "Panretin (Alitretinoin) Drug Information". RxList. November 21, 2000. http://www.rxlist.com/panretin-drug.htm. Retrieved 2009-01-14.
^ Ruzicka, Thomas, MD; Frederik Grønhøj Larsen, MD, PhD; Dorota Galewicz, MD; Attila Horváth, MD; Peter Jan Coenraads, MD; Kristian Thestrup-Pedersen, MD; Jean Paul Ortonne, MD; Christos C. Zouboulis, MD; Martin Harsch, PhD; Thomas C. Brown, PhD; Maurice Zultak, MD (2004). "Oral Alitretinoin (9-cis-Retinoic Acid) Therapy for Chronic Hand Dermatitis in Patients Refractory to Standard Therapy. Results of a Randomized, Double-blind, Placebo-Controlled, Multicenter Trial". Arch Dermatol 140: 14531459.
^ "NICE guidance documentation". http://www.nice.org.uk/guidance/index.jsp?action=byID&o=12035.